These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

139 related items for PubMed ID: 6108445

  • 21. The immunoprophylaxis and immunotherapy of Pseudomonas infections in burns with polyvalent Pseudomonas aeruginosa corpuscular vaccine.
    Ionescu A, Meitert E, Vasiliu S, Meitert T, Milicescu S, Sima F, Savulian C.
    Arch Roum Pathol Exp Microbiol; 1979; 38(3-4):317-30. PubMed ID: 122594
    [No Abstract] [Full Text] [Related]

  • 22. Anti-Pseudomonas immunoglobulin. III. Preliminary clinical evaluation.
    Sakiel S, Schiller B, Buchowicz I, Kotkowska-Tomanek E.
    Arch Immunol Ther Exp (Warsz); 1983; 31(4):517-21. PubMed ID: 6422901
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. Motility, virulence, and protection with a flagella vaccine against Pseudomonas aeruginosa infection.
    Montie TC, Drake D, Sellin H, Slater O, Edmonds S.
    Antibiot Chemother (1971); 1987; 39():233-48. PubMed ID: 3118785
    [No Abstract] [Full Text] [Related]

  • 25. Immunological control of Pseudomonas infection in burn patients: a clinical evaluation.
    Alexander JW, Fisher MW, MacMillan BG.
    Arch Surg; 1971 Jan; 102(1):31-5. PubMed ID: 4992359
    [No Abstract] [Full Text] [Related]

  • 26. [Results of using a polyvalent vaccine against Pseudomonas aeruginosa in patients with burns treated at various therapeutic centers in Poland].
    Bukowska D, Serafińska D, Zietkiewicz W, Rudowski W, Hoffman S, Uszyński H, Molski M, Hess C, Jonecko A, Popiel D.
    Pol Tyg Lek; 1986 Dec 08; 41(49):1549-52. PubMed ID: 3108869
    [No Abstract] [Full Text] [Related]

  • 27. [Use of a vaccine for prevention of Pseudomonas aeruginosa infection of burn wounds in mice].
    Grochowski J, Bilinska M, Stankiewicz D, Arkusiewicz E.
    Pol Przegl Chir; 1979 Jun 08; 51(6):623-7. PubMed ID: 116210
    [No Abstract] [Full Text] [Related]

  • 28. Vaccine prophylaxis for pseudomonas infections.
    Markley K.
    Ann Intern Med; 1971 Jan 08; 74(1):140. PubMed ID: 4992650
    [No Abstract] [Full Text] [Related]

  • 29. Pseudomonas vaccine and hyperimmune plasma for burned patients.
    Feller I, Pierson C.
    Arch Surg; 1968 Aug 08; 97(2):225-9. PubMed ID: 5657428
    [No Abstract] [Full Text] [Related]

  • 30. Systematic utilization of an antipseudomonas aeruginosa vaccine in a severe burn unit.
    Wassermann D, Schlotterer M, Paul P, Rieu M.
    Scand J Plast Reconstr Surg; 1979 Aug 08; 13(1):81-4. PubMed ID: 451484
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. [Dynamics of the contamination of mice during the treatment of burn sepsis due to Pseudomonas aeruginosa using tobramycin alone or combined with active and passive immunization].
    Minukhin VV, Tsyganenko AIa.
    Zh Mikrobiol Epidemiol Immunobiol; 1986 Sep 08; (9):90-2. PubMed ID: 3098009
    [Abstract] [Full Text] [Related]

  • 33. [Effectiveness of tobramycin and immunologic preparations in experimental Pseudomonas infection].
    Minukhin VV, Tsyganenko AIa.
    Antibiot Khimioter; 1989 Apr 08; 34(4):282-6. PubMed ID: 2502083
    [Abstract] [Full Text] [Related]

  • 34. Investigations on the efficacy of monovalent Pseudomonas aeruginosa vaccine for oral administration in Pseudomonas aeruginosa experimental infection.
    Meitert E, Sima F, Savulian C, Petrovici M, Chersulick E, Costache G.
    Arch Roum Pathol Exp Microbiol; 1989 Apr 08; 48(3):237-51. PubMed ID: 2519634
    [Abstract] [Full Text] [Related]

  • 35. [Use of human anti-Pseudomonas immunoglobulins in treatment of children with burns].
    Bukowska D, Wegrzynowicz Z, Rudowski W, Kraj M, Rosiek A, Gardzińska E, Popiel D.
    Pol Tyg Lek; 1996 Jun 08; 51(23-26):331-3. PubMed ID: 9273523
    [Abstract] [Full Text] [Related]

  • 36. Pseudomonas aeruginosa polysaccharide-tetanus toxoid conjugate vaccine: safety and immunogenicity in humans.
    Cryz SJ, Sadoff JC, Fürer E, Germanier R.
    J Infect Dis; 1986 Oct 08; 154(4):682-8. PubMed ID: 3091708
    [Abstract] [Full Text] [Related]

  • 37. Assessment of the effectiveness of antipseudomonas biological management in the control of infection in burn patients.
    Gonzáles Ayala SE, Daroda M, Villa J, Cecchini E, Vich J.
    Panminerva Med; 1983 Oct 08; 25(3):203-8. PubMed ID: 6422426
    [No Abstract] [Full Text] [Related]

  • 38. Passive immunisation against Pseudomonas aeruginosa recombinant flagellin in an experimental model of burn wound sepsis.
    Faezi S, Sattari M, Mahdavi M, Roudkenar MH.
    Burns; 2011 Aug 08; 37(5):865-72. PubMed ID: 21334822
    [Abstract] [Full Text] [Related]

  • 39. Prevention of invasive pseudomonas infection in burns with a new vaccine.
    Alexander JW, Fisher MW, MacMillan BG, Altemeier WA.
    Arch Surg; 1969 Aug 08; 99(2):249-56. PubMed ID: 4978523
    [No Abstract] [Full Text] [Related]

  • 40. Pseudomonas burn sepsis in patients treated with aqueous silver nitrate (0.5 percent).
    Tessler R, Polk HC.
    Surgery; 1967 May 08; 61(5):705-10. PubMed ID: 6024394
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 7.